

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/517,633	12/13/2004	Keiji Kamiyama	2004_1927A	1348	
	7590 03/14/200 I, LIND & PONACK, I	EXAMINER			
2033 K STREE SUITE 800	TN. W.	MORRIS, PATRICIA L			
	N, DC 20006-1021		ART UNIT	PAPER NUMBER	
			1625		
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
31 D	AYS	03/14/2007	DADED		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Applic	ation No.	Applicant(s)					
Office Action Comme		10/51	7,633	KAMIYAMA ET AL	KAMIYAMA ET AL.				
Office Action Summary			iner	Art Unit					
			a L. Morris	1625					
Period fo	The MAILING DATE of this communi or Reply	cation appears on	the cover sheet	with the correspondence add	dress				
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MANAGER, FROM THE MANAGER OF THE MANAGER	AILING DATE OF of 37 CFR 1.136(a). In nunication. tutory period will apply an will, by statute, cause the	THIS COMMU to event, however, may and will expire SIX (6) Me application to become	NICATION. y a reply be timely filed MONTHS from the mailing date of this co ABANDONED (35 U.S.C. § 133).					
Status									
1)[Responsive to communication(s) file	d on	-						
		b) This action	is non-final.						
3)[Since this application is in condition to	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)⊠	Claim(s) 1-24 is/are pending in the a	pplication.			•				
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)[5) Claim(s) is/are allowed.								
6)□	Claim(s) is/are rejected.								
7)⊠	☐ Claim(s) <u>16,18,22 and 23</u> is/are objected to.								
8)⊠	8) Claim(s) 1-15,19-21 and 24 are subject to restriction and/or election requirement.								
Applicati	on Papers			•					
9)	The specification is objected to by the	Examiner.							
10)	The drawing(s) filed on is/are:	a) accepted of	r b) objected	to by the Examiner.					
	Applicant may not request that any object	tion to the drawing	(s) be held in abe	yance. See 37 CFR 1.85(a).					
	Replacement drawing sheet(s) including	the correction is re-	quired if the drawi	ng(s) is objected to. See 37 CF	FR 1.121(d).				
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority u	ınder 35 U.S.C. § 119								
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a)[a)⊠ All b)□ Some * c)□ None of:								
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)).									
* See the attached detailed Office action for a list of the certified copies not received.									
				•					
Attachmen	t(s)								
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)									
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date Notice of Informal Patent Application									
Paper No(s)/Mail Date 6) Other:									

Art Unit: 1625

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, the instance wherein B is benzene.

Group II, the instance wherein B is a monocyclic aromatic heterocycle.

Group III, Claim 14 drawn to multiple processes.

Group IV, Claims 17 and 19, drawn to multiple packages.

Group V, Claims 20 and 21, drawn to multiple uses.

Group VI, claim 24, drawn to compositions containing an additional active ingredient.

Claims 16, 18, 22 and 23 are drawn to nonstatutory subject matter and hence, cannot be grouped at this time. In the event that applicants amend the claims, they will be grouped accordingly.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I, II and III are related as products and processes of preparing. In the instant case, the products as claimed can be made by materially different processes as evidenced by applicants'own claims and specification.

Art Unit: 1625

Groups I, II and V are related as products and multiple uses. In the instant case, the products have other uses as evidenced by applicants' own claims and specification.

Groups I, II and IV, VI are unrelated because Groups IV and VI require an additional active ingredient for their use. Groups I, II and IV, VI differ in scope.

Due to the numerous variables B, W, Z etc., and their widely divergent meanings, and the numerous methods of using, a precise listing of inventive groups cannot be made. Illustrative of different inventive concepts may be made by reference to the compounds in the Examples of the instant application, as for example:

the compounds of

- I. Example 1 used for the treatment of peptic ulcers,
- II. Example 12 used for the treatment of gastric cancer,
- III. Example 30 used for the treatment of peptic ulcers,
- IV. compounds wherein B is a monocyclic aromatic heterocycle are not exemplified, etc.,

The claims herein lack unity of invention under PCT Rule 13.1 and 13.2 since the compounds defined in the claims lack a significant structural element qualifying as the special technical feature that defines a contribution over the prior art. The compounds claimed contain a pyridine which does not define a contribution over the prior art. The substituents on the structure vary extensively and when taken as a whole result in vastly different compounds. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper.

In the event of any election of either Groups I or II, applicants are required to elect a single compound.

Claims 1-13 and 15 will be examined to the extent readable on the elected compounds.

37 CFR 1.475(b) an international or a national stage application containing claims drawn to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combination of categories:

- (1) A product and a process specifically adapted for the manufacture of said product;
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specifically adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.
- (c) If an application contains claims to more or less than one of the combination of categories of inventions set forth in paragraph (b) of this section, unity of invention might not be present.
- (d) If multiple products, processes of manufacture, or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories relied thereto will be considered as the main invention in the claims.
- (e) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claim or as alternatives within a single claim.

Art Unit: 1625

Once applicant has elected a compound from Groups I, II or III, he is permitted to have, in view of the fact that this application enters the national stage through 35 U.S.C. 371, no more than one process of preparing and one process of using that elected product. See PCT Rule 13.2.

Also, note 1134 OG 197, where it is specifically recited that under PCT Rule 13.2(i), claims are permitted to <u>one</u> product and <u>one</u> process of preparing.

In the event of an election of either Group I or II, applicant is also requested to elect one process of preparing and one method of use, *i.e.*, specific disease.

In the event of an election of Group VI, applicants are requested to elect a single disclosed mixture.

Because these inventions lack unity of invention for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter restriction for examination purposes as indicated is proper.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Application/Control Number: 10/517,633 Page 6

Art Unit: 1625

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant may file the divisional subject matter noted in divisional applications. If applicant wishes a generic expression of the elected invention the claims here need be amended to reflect that election.

This restriction requirement is being written as previous experience has indicated that with Foreign applicants and the inherent time delays, applicants' representative is better able to make an informed, correct, election of the invention applicants would wish to have prosecuted here if applicants are given the opportunity to see the restriction requirement laid out, and given the time to make an informed decision.

Art Unit: 1625

Applicant is advised that the response to this requirement to be complete must include an

Page 7

election of the invention to be examined even though the requirement be traversed (37)

CFR 1.143).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Patricia L. Morris whose telephone number is (571) 272-0688.

The examiner can normally be reached on Mondays through Fridays.

The fax phone number for the organization where this application or proceeding is

assigned is 571-272-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit 1625

March 7, 2007